Edition:
India

People: Galapagos NV (GLPG.AS)

GLPG.AS on Amsterdam Stock Exchange

143.50EUR
17 Sep 2019
Change (% chg)

€-0.90 (-0.62%)
Prev Close
€144.40
Open
€144.00
Day's High
€145.35
Day's Low
€142.30
Volume
208,034
Avg. Vol
373,753
52-wk High
€171.20
52-wk Low
€74.48

Bosley, Katrine 

Ms. Katrine Bosley has been Non-Executive Independent Director of Galapagos NV since February 27, 2013. She is Member of the Remuneration and Nomination Committee. She has served as the President, Chief Executive Officer and member of the board of directors of Editas Medicine, Inc. since June 2014. Prior to joining Editas, she was the Entrepreneur-in-Residence at The Broad Institute from 2013 to 2014. From 2009 to 2012, she was President, Chief Executive Officer and member of the board of directors of Avila Therapeutics, Inc., which was acquired by Celgene Corporation in 2012. She served as President, Celgene Avilomics Research at Celgene in 2012. Prior to her time at Avila Therapeutics she was Vice President, Strategic Operations at Adnexus, a Bristol-Myers Squibb R&D Company, and was Vice President, Business Development at Adnexus Therapeutics, Inc. before that. Ms. Bosley joined Adnexus Therapeutics from Biogen Idec, Inc. where she had roles in business development, commercial operations and portfolio strategy in the United States and Europe. Earlier, she was part of the healthcare team at the venture firm Highland Capital Partners, Inc. Ms. Bosley graduated from Cornell University with a B.A. in Biology. She currently serves as chairman of the board of Genocea Biosciences, Inc. She also serves on the board of directors of the Biotechnology Innovation Organization and of the Massachusetts Eye and Ear Institute.

Basic Compensation

Total Annual Compensation, EUR 45,000
Restricted Stock Award, EUR --
Long-Term Incentive Plans, EUR --
All Other, EUR --
Fiscal Year Total, EUR 45,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --